U.S. market Closed. Opens in 5 hours 24 minutes

MLYS | Mineralys Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 9.27 - 9.82
52 Week Range 8.58 - 16.91
Beta 1.47
Implied Volatility 705.07%
IV Rank 73.16%
Day's Volume 273,521
Average Volume 219,325
Shares Outstanding 49,768,670
Market Cap 486,239,906
Sector Healthcare
Industry Biotechnology
IPO Date 2023-02-10
Valuation
Profitability
Growth
Health
P/E Ratio -2.95
Forward P/E Ratio N/A
EPS -3.31
1YR Price Target N/A
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 28
Country USA
Website MLYS
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
*Chart delayed
Analyzing fundamentals for MLYS we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is weak. For more detailed analysis please see MLYS Fundamentals page.

Watching at MLYS technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on MLYS Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙